Cargando…

Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate

BACKGROUND: To determine the concentration after a single dose of generic 0.05% difluprednate and commercial difluprednate in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits, a preclinical study in 72 male New Zealand white rabbits was performed. A single dose (50 μL) of two 0.05%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercado-Sesma, Arieh, Contreras-Rubio, Angélica, Baiza-Durán, Leopoldo, Olvera-Montaño, Oscar, Miranda-Robles, Mónica, Bonilla-García, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360744/ https://www.ncbi.nlm.nih.gov/pubmed/28324274 http://dx.doi.org/10.1186/s12348-017-0127-2

Ejemplares similares

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana, Claudia, et al.
Publicado: (2020)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

The role of difluprednate ophthalmic emulsion in clinical practice
por: Jamal, Karim N, et al.
Publicado: (2009)

Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Quantz, Katelin, et al.
Publicado: (2021)

Topical difluprednate for the treatment of Harada’s disease
por: Onishi, Spencer M, et al.
Publicado: (2015)

A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%
por: Kusne, Yael, et al.
Publicado: (2016)

Difluprednate for the prevention of ocular inflammation postsurgery: an update
por: Donnenfeld, Eric D
Publicado: (2011)

Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis
por: Wang, Jay C., et al.
Publicado: (2016)

Therapeutic Efficacy of Difluprednate 0.05% Versus Prednisolone Acetate 1% in Controlling Inflammation and Macular Oedema Following Phacoemulsification: An Optical Coherence Tomography-Based Study
por: Panda, Bijnya B, et al.
Publicado: (2021)

Topical Difluprednate for Early Corneal Graft Rejection After Penetrating Keratoplasty
por: Said, Omar M, et al.
Publicado: (2020)

Cytomegalovirus retinitis after treatment with topical difluprednate in an aphakic eye of an immunocompetent patient
por: Kaplan, Richard I., et al.
Publicado: (2019)

Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis
por: KhalafAllah, Mahmoud Tawfik, et al.
Publicado: (2019)

Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate
por: Chalam, KV, et al.
Publicado: (2012)

Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study
por: Wilson, M E, et al.
Publicado: (2016)

Tumors of the conjunctiva and cornea
por: Shields, Carol L, et al.
Publicado: (2019)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Hexamethylene Tetramine in Septic Inflammations of the Cornea and Conjunctiva
por: Kirkpatrick, H.
Publicado: (1915)

Scarlet R. in Certain Diseases of the Conjunctiva and Cornea
por: Kirkpatrick, H.
Publicado: (1917)

On a Case of Melanotic Sarcoma of the Conjunctiva and Cornea
por: Meighan, T. S.
Publicado: (1879)

Double-masked, sham and placebo-controlled trial of corneal cross-linking and topical difluprednate in the treatment of bacterial keratitis: Steroids and Cross-linking for Ulcer Treatment Trial (SCUT II) study protocol
por: Radhakrishnan, Naveen, et al.
Publicado: (2021)

On Iodoform as a Remedy in the Treatment of Affections of the Cornea and Conjunctiva
Publicado: (1875)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

An Update on Ocular Surface Epithelial Stem Cells: Cornea and Conjunctiva
por: Ramos, Tiago, et al.
Publicado: (2015)

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
por: Byun, Yong-Soo, et al.
Publicado: (2011)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea
por: Al-Barrag, Abdulmoghni, et al.
Publicado: (2010)

Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
por: Chaugule, Sonal S, et al.
Publicado: (2018)

Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
por: Baiza-Durán, Leopoldo M., et al.
Publicado: (2023)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee, Michelle K, et al.
Publicado: (2017)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient
por: Barot, Rakesh K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6g5e091q7k3vcaf8d1qno18pfe